Alirocumab  (Synonyms: 阿利西尤单抗; REGN 727; SAR 236553)

Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia^{[1][2][3][4][5]}.

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Alirocumab (0.01, 0.1, 1, 2和10 μM, 24-72 h) 在 hiPSC-CMs 和 hESC-CMs 中不影响细胞活力和功能，可用于评估降脂心血管细胞中的药物安全性^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Alirocumab (3或10 mg/kg, 每周皮下注射持续18周) 在小鼠中可抑制动脉粥样硬化，改善斑块形态，增强他汀类药物的作用^[4]。
Alirocumab (10 mg/kg, 第 0, 10, 20 天腹腔注射) 在大鼠中可通过抑制 PCSK9 改善 BDL 诱导的肝硬化大鼠的全身氧化应激和高脂血症^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1245916-14-6

液体

Colorless to light yellow

阿利西尤单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705.  [Content Brief]

  [2]. Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44.  [Content Brief]

  [3]. Ni X, et al. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta Pharmacol Sin. 2022 Jan;43(1):240-250.  [Content Brief]

  [4]. Kühnast S, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014 Oct;55(10):2103-12.  [Content Brief]

  [5]. Huang HC, et al. Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int J Mol Sci. 2022 Jul 2;23(13):7378.  [Content Brief]